The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time trend in the survival advantage in phase III trials investigating molecular-targeted agents for advanced non-small cell lung cancer (NSCLC) during the past decade.
Yuka Kato
No relevant relationships to disclose
Katsuyuki Hotta
No relevant relationships to disclose
Hiroe Kayatani
No relevant relationships to disclose
Toshio Kubo
No relevant relationships to disclose
Kadoaki Ohashi
No relevant relationships to disclose
Masahiro Tabata
No relevant relationships to disclose
Mitsune Tanimoto
No relevant relationships to disclose
Katsuyuki Kiura
No relevant relationships to disclose